A bit to consider perhaps3 Oct 2020 10:44
I am sure there will some smug gurning that risk has been brought up again – it comes up on a cycle with favourites such as –
1) ‘lifestyle management’ (blown away by the progress now coming to fruition after years of very careful work),
2) ‘no major investors’ (just don’t mention Vulpes and Redmile for starters), ‘no money’ (apart from 20 million quid in the bank and a history of careful financial management),
3) ‘no outside interest’ (apart from Redmile and co, plus the 2.7 million grant for the vaccine, and that’s disregarding CRUK, Biontech, Roche, Keith Flaherty etc)
4) ‘no director buying’ – which would be met with ‘trying to pump the company because nobody else will buy’ (but see Redmile, Vulpes, oversubscribed open offer, government funding as before) and difficult to be allowed to increase holdings when negotiating with a major specialist US investment fund, government sources, vaccine manufacturers, and who knows what else at this busy time
It is reasonable to consider risk, but an argument has credibility if backed up with facts. ‘Facts’ does not mean a short post with the words ‘this is a very high risk play’ and then a line later saying ‘It is a very very high risk play’ and nothing else.
Risk is subjective – repetition of ‘very (or very very) high risk play’ is like crossing the road and someone saying ‘Don’t go near the road, it’s dangerous – people die there.’ It ignores the difference between wandering across a motorway blindfolded and as drunk as a share pundit, versus using a Pelican crossing on a straight road on a Sunday lunchtime.
Without going through progress on all Scancell’s platforms (multiple platforms being less risky than a single one) let’s just briefly consider Covidity – Very rapid developments, attracted government funding, vaccine production signed up, and derived from a platform that is proven with in-human clinical results which are ‘well beyond the established norms.’ (The words of a world respected individual in the cancer field). Results with the swimmer chart to show the success, 7 year survival from previously terminal patients etc etc – It’s been aired here so often, and always in response to soemone who spends half his time shouting ‘risk risk risk’ without specific facts, at best just generalisations and sometimes (as yesterday) just repeating ‘very very risky.’ I suppose it makes a change from repeating ‘buy buy buy’, a mantra which has only occurred in his posts for years, allegedly quoting others, but in fact just plucked from a vindictive cloud. There’s nothing like being balanced, but Knowlesi you’re nothing like. There are so many facts to show that Scancell are highly respected, very investable and making excellent progress, so by all means debate, but with facts, not fiction. But as ever – Do Your Own Research. Try it Knowlesi, you might be surprised at what facts you find. Nanny will pick your teddy up.
Sign In
Follow the stocks
